New approaches to chemotherapy-induced nausea and vomiting: From neuropharmacology to clinical investigations

Cancer Journal

Volumn 12, Issue 5, 2006, Pages 341-347

  Rubenstein, Edward B ^a   Slusher, Barbara S ^b   Rojas, Camilo ^b   Navari, Rudolph M ^c  

^a GUILFORD PHARMACEUTICALS INC   (United States)

^b Research and Development   (United States)

^c UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Cancer; Chemotherapy; Emesis; Nausea; Vomiting

Indexed keywords

2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; DRONABINOL; GABAPENTIN; GRANISETRON; INDOMETACIN; LEVOMEPROMAZINE; MELOXICAM; METOCLOPRAMIDE; METOPIMAZINE; MIDAZOLAM; NABILONE; NABUMETONE; OLANZAPINE; ONDANSETRON; PALONOSETRON; RESINIFERATOXIN; SEROTONIN 3 ANTAGONIST; SUBSTANCE P; VENLAFAXINE; ZACOPRIDE;

ARTICLE; CANCER; CANCER THERAPY; CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; HUMAN; MENTAL DISEASE; NAUSEA AND VOMITING; NEUROPHARMACOLOGY; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL;

EID: 33749857161     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200609000-00003     Document Type: Article

References (48)

1. Hesketh PJ. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress. Oncology (Williston Park) 2004;18(10 Suppl 6):9-14.
2. Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111 (Suppl 8A):106S-112S.
3. Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs 1983;25 Suppl 1:63-73.
4. Burks TF. Drugs affecting gastrointestinal motility and antiemetic agents. In Munson PL, Breese GR, Mueller RA, eds. Principles of Pharmacology: Basic Concepts and Clinical Applications. New York: Chapman & Hall, 1996.
5. Bianchi C, Beani L, Crema C. Effects of metoclopramide on isolated guinea-pig colon. 2. Interference with ganglionic stimulant drugs. Eur J Pharmacol 1970;12(3):332-341.
6. Fontaine J, Reuse JJ. Pharmacological analysis of the effects of metoclopramide on the guinea-pig ileum in vitro. Arch Int Pharmacodyn Ther 1973;204(2):293-305.
7. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 1986;88(3):497-499.
8. Cubeddu LX. Mechanisms by which cancer chemotherapeutic drugs induce emesis. Semin Oncol 1992;19(6 Suppl 15):2-13.
9. Rudd JA, Andrews PLR. Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In Hesketh PJ, ed. Management of Nausea and Vomiting in Cancer and Cancer Treatment. Sudbury, MA: Jones and Bartlett Publishers, Inc., 2005.
10. Hickok JT, Roscoe JA, Morrow GR et al. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97(11):2880-2886.
11. Rubenstein EB. Costs and benefits of outpatient therapy. Support Care Cancer 1994;2(5):307-311.
12. Cancer Care Ontario Practice Guidelines Initiative: Use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy. Practice Guideline Report #12-3. http://wwwcancercareonca/pdf/pebc12_3fpdf 2003:1-24.
13. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89(11):2301-2308.
14. Bloechl-Daum B, Deuson RR, Mavros P et al. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetric treatment. J Clin Oncol, in press.
15. Siddiqui MA, Scott LJ. Palonosetron. Drugs 2004;64(10):1125-1132; discussion 1133-1134.
16. Aapro M. Serotonin receptor antagonists. In Hesketh PJ, ed. Management of Nausea and Vomiting in Cancer and Cancer Treatment. Sudbury, MA: Jones and Bartlett Publishers, Inc., 2005.
17. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 2004;15(2):330-337.
18. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14(10):1570-1577.
19. Wong EH, Clark R, Leung E et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 1995;114(4):851-859.
20. Constenla M. 5-HT3 receptor antagonists for prevention of late acute-onset emesis. Ann Pharmacother 2004;38(10):1683-1691.
21. Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res 1984;11(3):277-281.
22. Bountra C, Bunce K, Dale T et al. Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249(1):R3-R4.
23. Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250(1):R5-R6.
24. Guttuso T, Jr., Roscoe J, Griggs J. Effect of gabapentin on nausea induced by chemotherapy in patients with breast cancer. Lancet 2003;361(9370):1703-1705.
25. Mandala M, Cremonesi M, Rocca A et al. Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 2005;13(6):375-380.
26. Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001;24(2):198-203.
27. Van Sickle MD, Oland LD, Ho W et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001;121(4):767-774.
28. Andrews PL, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993;32(8):799-806.
29. Bloch J, Rixe O, Meric JB et al. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin 2005;21(11):1763-1771.
30. McCabe HL, Maraveyas A. Subcutaneous levomepromazine rescue (SLR) for high grade delayed chemotherapy-induced emesis (DCIE). Anticancer Res 2003;23(6D):5209-5212.
31. Passik SD, Kirsh KL, Theobald DE et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 2003;25(5):485-488.
32. Navari R, Einhorn L, Loehrer P et al. A phase II trial of olanzapine (Zyprexa) and palonosetron (Aloxi) for the prevention of chemotherapy induced nausea and vomiting (CINV). Proc Am Soc Clin Oncol 2004:Abstract # 8046.
33. Navari RM. et al. J Clin Oncol 2006;24(suppl):18S. Abstract 8606.
34. Navari RM, Province PS. Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs 2006;11(1):137-151.
35. Girod V, Dapzol J, Bouvier M, Grelot L. The COX inhibitors indomethacin and meloxicam exhibit anti-emetic activity against cisplatin-induced emesis in piglets. Neuropharmacology 2002;42(3):428-436.
36. Kudo C, Minami M, Hirafuji M et al. The effects of nabumetone, a cyclooxygenase-2 inhibitor, on cisplatin-induced 5-hydroxytryptamine release from the isolated rat ileum. Res Commun Mol Pathol Pharmacol 2001;110(1-2):117-132.
37. Lehmann A, Karrberg L. Effects of N-methyl-D-aspartate receptor antagonists on cisplatin-induced emesis in the ferret. Neuropharmacology 1996;35(4):475-481.
38. 3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus. Jpn J Pharmacol 2001;85(1):70-74.
39. Grelot L, Milano S, Stunff HL. Does 5-HT play a role in the delayed phase of cisplatin-induced emesis? In Reynolds DJM, Andrews PLR, Davis CJ, eds. Serotonin and the Scientific basis of Anti-Emetic Therapy. Oxford, UK: Oxford Clinical Communications; 1995.
40. Yamakuni H, Nakayama H, Matsui S et al. Inhibitory effect of zacopride on cisplatin-induced delayed emesis in ferrets. J Pharmacol Sci 2006;101:99-102.
41. Showell GA, Barnes MJ, Daiss JO et al. (R)-sila-venlafaxine: a selective noradrenaline reuptake inhibitor for the treatment of emesis. Bioorg Med Chem Lett 2006;16(9):2555-2558.
42. Hu WP, You XH, Guan BC et al. Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci Lett 2004;365(2):147-152.
43. Moore KA, Oh EJ, Weinreich D. 5-HT(3) receptors mediate inflammation-induced unmasking of functional tachykinin responses in vitro. J Appl Physiol 2002;92(6):2529-2534.
44. Moore KA, Taylor GE, Weinreich D. Serotonin unmasks functional NK-2 receptors in vagal sensory neurones of the guineapig. J Physiol 1999;514 (Pt 1):111-124.
45. Minami M, Endo T, Yokota H et al. Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 2001;428(2):215-220.
46. Erspamer V, Testini A. Observations on the release and turnover rate of 5-hydroxytryptamine in the gastrointestinal tract. J Pharm Pharmacol 1959;11:618-623.
47. Kaiser R, Sezer O, Papies A et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002;20(12):2805-2811.
48. Tremblay PB, Kaiser R, Sezer O et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 2003;21(11):2147-2155.